

**REMARKS**

Claims 38-46, 48-65, and 69-78 were pending in the instant application. Applicants note that the Examiner did not address claims 77-78 in the November 26, 2002 Office Action. It is the Applicants' understanding, however, that the Examiner indicated in a November 14, 2002 telephone conference with Applicants' previous attorney, that claims 77-78 are in condition for allowance. By this Amendment, Applicants have canceled claims 46, 48, and 73-76 without prejudice. Claim 71 has been amended to change its dependency from previously canceled claim 67 to claim 69. Applicants assert that the amendment does not introduce any new matter, and thus, its entry is requested. Upon entry of the present Amendment, claims 38-45, 49-65, 69-72, and 77-78 will be pending and under examination.

**Examiner's Responses to Previous Amendment**

The Examiner withdrew the finality of the previous Office Action. The Examiner indicated that Applicants' claim amendments filed October 28, 2002 have overcome the rejections under 35 U.S.C. § 112, first paragraph, the rejections under 35 U.S.C. § 112, second paragraph, the rejections under 35 U.S.C. § 103, and the objections that were set forth in the previous Office Action.

In response, Applicants acknowledge and appreciate the withdrawal of these rejections and objections.

**Examiner's Objections**

The Examiner objected to claim 48 because of its dependence on canceled claim 47. The Examiner objected to claim 71 because of its dependence on canceled claim 67.

In response, Applicants have canceled claim 48 without prejudice and have amended claim 71 to make it dependent on claim 69. Applicants believe that the cancellation of claim 48 and the amendment to claim 71 obviate these objections, and thus, respectfully request that the objections be withdrawn.

**Examiner's Rejection Under 35 U.S.C. § 112, first paragraph--written description**

The Examiner rejected claims 46, 48, and 73-76 under 35 U.S.C. § 112, first paragraph as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors had possession of the claimed invention.

In response, without conceding the correctness of the Examiner's position, but to advance prosecution of the subject application, Applicants have canceled claims 46, 48, and 73-76. Applicants reserve the right to file a divisional application directed thereto.

**Examiner's Rejection under 35 U.S.C. § 112, first paragraph--enablement**

The Examiner rejected claims 63-65 and 71-72 as allegedly containing subject matter that was not described in the specification in such a way as to enable one skilled in the art to make and/or use the invention.

Specifically, the Examiner took the position that the claims are not enabled because vaccine making is a poorly enabled art which relies heavily on a trial and error process for discovery and development. The Examiner stated that the instant claims, drawn to a vaccine, do not provide the necessary information for the making of any vaccine, and thus, to make one would require undue experimentation. The Examiner pointed to the complexity of the invention and the general uncertainty and unpredictability involved in making a vaccine.

In response, Applicants respectfully traverse the rejection of claims 63-65 and 71-72. The claims as written are fully enabled by the specification. Applicants first direct the Examiner's attention to the detailed discussion of the claimed vaccine compositions set forth in the specification at pages 8-11. These pages describe how to prepare bacterial ghosts as vaccines, using the operator sequences of the present invention, and notes that ghost cells have been known in the art to be useful as vaccines. The Applicant has previously submitted references showing this to be the case. Applicant again submits herewith a recent publication, entitled "Generation of *Helicobacter pylori* Ghosts by PhiX Protein E-Mediated Inactivation and Their Evaluation as Vaccine Candidates," which further demonstrates the enablement of the present claims. This publication demonstrates the efficacy of a *Helicobacter* ghost vaccine generated by using the temperature-sensitive  $\lambda$  operator sequence of the present invention (see, e.g. Fig. 1). Moreover, the specification, at pages 10-11, describes vaccine compositions in which the active ingredient is a bacterial cell in accordance with the invention, specifically reciting several such cells suitable as vaccines. Accordingly, Applicants assert that the claimed vaccine compositions are fully enabled by the specification and that such enablement has in fact

been demonstrated in the literature. Applicants, therefore, respectfully request that the Examiner reconsider and withdraw the rejection of claims 63-65 and 71-72 under 35 U.S.C. §112, first paragraph.

**Allowable Subject Matter**

The Examiner has allowed claims 38-45, 49-62, 69, and 70. As noted above, the Examiner had previously indicated that claims 77-78 are also allowable.

Applicants acknowledge and appreciate the allowance of these claims.

In view of the above remarks and amendments, Applicants believe that the Examiner's rejections and objections set forth in the November 26, 2002 Office Action have been overcome and that the present application is in condition for allowance. The Examiner is invited to telephone the undersigned if it is deemed to expedite allowance of the application.

Respectfully submitted,



Patrick T. Skacel  
Registration No. 47,948  
Attorney for Applicants  
Rothwell, Figg, Ernst & Manbeck, P.C.  
1425 K Street, N.W., Suite 800  
Washington, DC 20005  
Telephone: (202) 783-6040  
Fax: (202) 783-6031

Date: February 26, 2003

Attachments:  
Marked-Up Copy of amendments  
January 2003 publication

2923-308.aml



U.S. Appln. No. 09/147,693  
February 26, 2003  
Page 7

**Marked-up Copy of Amended Claim 71**

71. (Amended) A vaccine composition, comprising a live bacterial cell according to claim [67]69 in combination with pharmaceutically acceptable auxiliary substances, additives or carrier substances.

RECEIVED  
FEB 28 2003  
TECH CENTER 1600/2300

## Generation of *Helicobacter pylori* Ghosts by PhiX Protein E-Mediated Inactivation and Their Evaluation as Vaccine Candidates

Klaus Panthel,<sup>1</sup> Wolfgang Jechlinger,<sup>2</sup> Alexander Matis,<sup>2</sup> Manfred Rohde,<sup>3</sup> Michael Szostak,<sup>4</sup> Werner Lubitz,<sup>2,4</sup> and Rainer Haas<sup>1\*</sup>

Max von Pettenkofer Institute for Hygiene and Medical Microbiology, LMU Munich,<sup>1</sup> and Department of Microbial Pathogenicity and Vaccine Research, GBF Braunschweig,<sup>2</sup> Germany, and Institute of Microbiology and Genetics, University of Vienna,<sup>3</sup> and BIRD-C GmbH,<sup>4</sup> Vienna, Austria

Received 22 July 2002/Returned for modification 24 September 2002/Accepted 15 October 2002

Bacterial ghosts are empty cell envelopes, which may be generated by the controlled expression of the PhiX174 lysis gene *E* in gram-negative bacteria to obtain vaccine candidates. We describe here the application of this technology to *Helicobacter pylori*. The lysis gene cassette was cloned into an *Escherichia coli*-*Helicobacter pylori* shuttle vector and introduced into an *H. pylori* recipient strain by bacterial conjugation. Temperature induction of the lysis gene cassette revealed a quantitative killing of the *H. pylori* culture without induction of lysis-resistant bacteria. Biochemical and transmission electron microscopic studies identified structurally intact *H. pylori*. Prophylactic oral vaccination experiments using these *H. pylori* ghosts in the BALB/c mouse model showed a significant reduction of the bacterial load in the ghost group, as measured by a quantitative bacterial reisolation procedure. Ten of 10 and 5 of 10 mice were protected, respectively, without the use of a mucosal adjuvant. Coadministration of ghosts with cholera toxin as mucosal adjuvant resulted in a complete protection of 10 of 10 and 8 of 8 mice against *H. pylori* challenge, with three animals showing a sterile immunity.

*Helicobacter pylori*, a prevalent gram-negative bacterium, infects half of the world's population, causing chronic active gastritis, which usually persists throughout life, unless the organism is eradicated (47). Although most infected individuals experience no symptoms, 15 to 20% develop peptic ulcer disease (41). Furthermore, chronic *H. pylori* infection confers a 3- to 12-fold increased risk of developing gastric malignancies, such as adenocarcinoma and low-grade B-cell lymphoma (16, 35, 43).

The use of vaccines for treatment and prevention of *H. pylori* infection has been explored as an alternative to standard multidrug regimens (10). The latter are known to induce antibiotic resistance in *H. pylori* strains (23) and cause the risk of reinfection following eradication (40). Animal studies have shown that immunization with *H. pylori* whole-cell sonicates or purified components is efficient for the prevention of infection, and, more importantly, for the treatment of preexisting infections (5, 8, 12, 14, 28, 31, 32, 50). All successful vaccination protocols included mucosal adjuvants, such as cholera toxin (CT) or *Escherichia coli* heat-labile toxin (LT), in addition to the antigen. Since CT and LT, and even the genetically detoxified forms of these adjuvants, induce diarrhea in humans (24, 33), it would be desirable to engineer a vaccine without the need of these adjuvants.

One attractive possibility includes the use of recombinant vaccine carrier strains that produce defined *H. pylori* vaccine antigens. Attenuated *Salmonella* vaccine strains (*phoP*<sup>−</sup> *araA*) producing the *H. pylori* UreA and UreB subunits can induce protection in mice without the need of a mucosal adjuvant (6,

17). The purpose of the present study was to generate and test a certain form of inactivated bacteria, so-called "bacterial ghosts," and test them for their potential to induce a prophylactic protection against a challenge with *H. pylori* in the well-established BALB/c mouse model.

Ghosts are empty bacterial cell envelopes without cytoplasm and DNA (46). They are generated by the tightly controlled expression of the cloned lysis gene *E* of bacteriophage PhiX174. The gene *E*-encoded protein was suggested to form a transmembrane tunnel in the bacterial cell wall, through which the cytoplasmic contents are expelled (46). Recent data by Bernhardt et al. (3) suggest that the lysis protein inhibits cell wall synthesis and thus kills the bacteria. Although the mechanism of genetic inactivation is still a matter of debate, the advantage of ghosts is that they share functional and antigenic determinants of the envelope with their living counterparts and thus represent ideal vaccine candidates.

Ghosts have been successfully generated in several gram-negative bacteria, such as *Escherichia coli*, *Salmonella enterica* serovar Typhimurium, *Vibrio cholerae*, *Klebsiella pneumoniae*, and *Actinobacillus pleuropneumoniae* (46). We demonstrate here for the first time the generation of inactivated *H. pylori* ghosts and show that they are able to protect mice against an oral challenge with an infectious dose of *H. pylori*.

### MATERIALS AND METHODS

**Bacterial strains and growth conditions.** *H. pylori* strains were grown on OC agar plates (Difco) supplemented with horse serum (8%), vancomycin (10 mg/liter), trimethoprim (5 mg/liter), and nystatin (1 mg/liter) (serum plates) and incubated for 24 to 48 h in a microaerophilic atmosphere (85% N<sub>2</sub>, 10% CO<sub>2</sub>, 5% O<sub>2</sub>) at 37°C. *H. pylori* strain P76 was originally obtained from H. Kleemann, OraVax, Inc., and transformed to streptomycin resistance for optimal quantitative reisolation from the infected mouse stomach by streptomycin selection (250 mg/liter) (serum plates/strep). P79 is a derivative of *H. pylori* P1 transformed to streptomycin resistance with chromosomal DNA of a streptomycin-resistant *H. pylori* strain, NCTC 11637. *E. coli* strain DH5α (BRL) was grown on Luria-

\* Corresponding author. Mailing address: Max von Pettenkofer-Institute for Hygiene and Medical Microbiology, Pettenkoferstr. 9a, D-80336 Munich, Germany. Phone: (49)-89-5160 5255. Fax: (49)-89-5160 5223. E-mail: haas@m3401.mpk.med.uni-muenchen.de.




FIG. 1. Genetic map of pHP38 carrying the  $\Phi$ X174 gene *E* lysis cassette under control of the temperature-sensitive ( $\lambda$ ) repressor binding to the  $\lambda$  promoter/operator region (left). The lysis cassette is carried by the pHel2 shuttle vector with replication functions for *E. coli* and *H. pylori* (right). *catG*, chloramphenicol acetyltransferase gene.

Bertani (LB) agar plates or in LB liquid medium (38) supplemented with chloramphenicol (30  $\mu$ g/ml). Strain 82155 (9) was grown on the same medium supplemented with diaminopimelic acid (0.2 mM).

**DNA manipulations.** Standard cloning and DNA analysis procedures were performed according to Sambrook et al. (38). Plasmid DNA was purified from *E. coli* by the boiling procedure, and *E. coli* cells for electroporation were prepared according to the protocol recommended for the Gene Pulser (Bio-Rad). Plasmid DNA was isolated from *H. pylori* strains by using Wizard minipreps (Promega) according to the protocol of the manufacturer.

**Plasmid construction.** Plasmid pHP38 is the product of subcloning a 2.4-kb *DnaI* fragment of plasmid pAWC10 (unpublished data) into the unique *Bam*HI restriction site of the *E. coli*-*H. pylori* shuttle vector pHel2, whereas the *Bam*HI sticky ends of pHel2 have been made blunt by a Klenow fill-in reaction. Plasmid pAWC10, in analogy to plasmid pAWJ (22), carries the *E*-lysis cassette consisting of gene *E*, the lambda cI857 repressor gene, and the  $\lambda$ P<sub>RM</sub> promoter, which has been modified by a single-base-pair exchange to allow repression of the lethal gene *E* at temperatures up to 38°C.

**Natural transformation and bacterial conjugation.** Shuttle and suicide plasmids were introduced into *H. pylori* strains by conjugation or natural transformation as described previously (15). *H. pylori* transformants or transconjugants carrying the shuttle plasmid pHP38 were selected on serum plates containing 6 mg of chloramphenicol per liter.

**SDS-PAGE and immunoblotting.** Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the method of Laemmli (26) with a mini-slab apparatus. Proteins separated by SDS-PAGE were transferred to nitrocellulose membranes in a semidry blot apparatus at a current density of 0.8 mA/cm<sup>2</sup>. Unreacted sites of the nitrocellulose membrane were blocked with a 3% (wt/vol) solution of bovine serum albumin (BSA) in TBS (20 mM Tris-HCl [pH 7.5], 150 mM NaCl). The nitrocellulose membrane was then incubated with an appropriate dilution of antibody for 2 h and washed three times with TBS containing 0.5% (vol/vol) Tween 20. Subsequently, alkaline phosphatase conjugated to protein A was added to TBS containing 3% (wt/vol) BSA. After incubation for 1 h, the nitrocellulose membrane was washed three times with TBS containing 0.5% (vol/vol) Tween 20 and developed with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium.

**Electron microscopic analysis.** For negative staining, thin carbon support films were prepared by indirect sublimation of carbon on to freshly cleaved mica. Samples were then absorbed to the carbon film and negatively stained with 1% (wt/vol) aqueous uranyl acetate (pH 4.5), as described previously (49). After air drying, samples were examined by transmission electron microscopy (TEM) in a Zeiss TEM 910 at an acceleration voltage of 80 kV. For embedding, after fixation of samples in 1% formaldehyde, samples were dehydrated in a graded series of acetone and embedded with Spurr epoxy resin according to the described protocol (42). Ultrathin sections were counterstained with uranyl acetate and lead citrate before examination in a Zeiss TEM 910.

**Animals.** Age-matched (6 to 8 weeks) female BALB/c mice were obtained from RCC, Itingen, Switzerland. All protocols involving animal experimentation were approved by the Regierung von Oberbayern (Aktenzeichen 211-2531-60/98).

**Growth of *H. pylori* for oral infection of mice.** For infection of mice, strain P76 was grown for 2 days on serum plates/strep at 37°C, harvested, and suspended in Brucella broth (Oxoid, Ltd., Basingstoke, England), and the final concentration was adjusted to  $3.3 \times 10^9$  cells per ml. Mice were inoculated three times intragastrically at 2-day intervals with 0.3 ml of bacterial suspension ( $10^9$  bacteria).

**Preparation of *H. pylori* ghosts.** *H. pylori* P79(pHP38) was grown on Brucella broth agar plates containing 10% horse serum and chloramphenicol (10  $\mu$ g/ml). After a 2-day incubation at 36°C under a microaerobic atmosphere, cells were harvested in 10 ml of brain heart infusion (BHI) supplemented with 10% fetal calf serum and chloramphenicol (10  $\mu$ g/ml) and grown for another 5 h under mild agitation (90 rpm). Before the culture reached the late-logarithmic growth phase, 10 to 50 ml of fresh medium was added. By repeating the addition of increasing amounts of fresh medium, the culture thus was expanded to 3.5 liters. When the growing culture reached an optical density at 600 nm (OD<sub>600</sub>) of 0.5, the incubation temperature was shifted up to 42°C to induce the gene *E*-mediated lysis process. After another 15 h of incubation at 42°C with monitoring of the OD<sub>600</sub>, the lysed culture was harvested. A centrifugation step (4°C, 10,000  $\times$  g, 10 min) served to pellet the ghosts, which were then resuspended in 100 ml of ice-cold phosphate-buffered saline (PBS). After the centrifugation and resuspension had been repeated twice more, the numbers of ghosts were determined under the microscope with a Thomas counting chamber, and aliquots of  $2.5 \times 10^9$  ghosts per 100  $\mu$ l were stored at -70°C until use.

**Infection and reisolation of bacteria and quantitative culture.** At the endpoint of the experiment, mice were anesthetized by CO<sub>2</sub> and sacrificed by cervical dislocation. The stomach was removed, weighed, and opened along the great curvature. For assessment of *H. pylori* colonization by quantitative culture, weighed stomachs were homogenized in 2 ml of Brucella broth by a hand homogenizer (Fisher Scientific, Germany), and serial dilutions of 1 in 20 were spread over the surface of serum plates/strep (performed in duplicate). The plates were incubated for 5 days, and colonies were counted to determine the number of CFU per gram of stomach tissue.

**Statistical analysis.** In the vaccination experiments, statistical significance between the groups was determined by the nonparametric Wilcoxon signed-rank (two-tailed) test. *P* values of <0.05 are considered as significantly different.

## RESULTS

**Construction of a plasmid-based  $\Phi$ X174 gene *E* lysis cassette for generation of *H. pylori* ghosts.** The *E. coli*-*H. pylori* shuttle plasmid pHel2 was used as the basis for the construction of an *H. pylori* lysis plasmid. This vector allows stable replication in both *E. coli* and *H. pylori* (20). The  $\Phi$ X174 lysis gene cassette consists of the  $\Phi$ X174 gene *E*, which is under the transcriptional control of the  $\lambda$ P<sub>RM</sub> promoter.  $\lambda$ P<sub>RM</sub> is a  $\lambda$ P<sub>R</sub> promoter with a point mutation in the operator region leading to efficient repression by cI857 at higher temperatures than with the wild-type operator sequence. The promoter is repressed by binding of cI857 to the operator region at temperatures <38°C and induced at temperatures >38°C (22). The cI857 temperature-sensitive  $\lambda$  repressor is transcribed by the  $\lambda$ P<sub>RM</sub> promoter in the opposite direction (Fig. 1). The  $\Phi$ X174 lysis gene cassette was ligated into the *Bam*HI site of the multiple cloning site of shuttle plasmid pHel2 and transformed into *E. coli* DH5 $\alpha$ . At temperatures below 38°C, re-




FIG. 2. Growth and lysis curves of *E. coli* DH5α and *H. pylori* P79 harboring plasmid pHPC38 by temperature induction of gene *E* expression. (A) At time zero, the cultures were shifted from 28°C to 42°C. ■, DH5α(pHPC38); ●, DH5α(pHel2). Prolonged incubation at 42°C (up to 24 h) leads to a recovery of the culture DH5α(pHPC38) due to the emergence of lysis-resistant bacteria. (B) The *H. pylori* culture was grown at 35°C and shifted at time zero to 42°C. ■, *H. pylori* P79(pHPC38); ●, P79(pHel2). Prolonged incubation at 42°C (up to 48 h) does not lead to recovery of the culture P79(pHPC38).

combinant plasmids could be isolated. One such plasmid, characterized by restriction analysis and designated as pHPC38, was used for all further experiments (Fig. 1).

**Testing of the lysis gene cassette in *E. coli* by temperature induction.** The functional expression of gene *E* from plasmid pHPC38 was tested in *E. coli* DH5α by growing the bacteria in LB medium and monitoring their growth by measuring the ODs of the culture at various time points (OD<sub>550</sub>). As a control, DH5α(pHel2) was used. The cultures were shifted from 28°C to 42°C at 0 h, which resulted in the functional inactivation of the cI857 repressor and transcription of *E* by the  $\Delta P_{R_{mut}}$  promoter. After induction at 42°C, the OD of DH5α [pHPC38] increased to an OD<sub>550</sub> of 1.25 within 1 h, but dropped rapidly to 0.6 (Fig. 2A). Strain DH5α carrying the cloning vector pHel2 alone showed a strong increase in its OD at the same time interval (OD<sub>550</sub> = 1.9). DH5α(pHPC38) grown at the permissive temperature of <38°C showed growth characteristics similar to those of the control strain DH5α(pHel2) without lysis gene expression (data not shown). In *E. coli*, which is the natural host of bacteriophage PhiX174, mutant lysis-resistant bacteria had already appeared several hours after induction (data not shown). The experiment demonstrated both that the lysis gene cassette cloned in the *E. coli*-*H. pylori* shuttle vector was induced under the elevated temperature and that the system was functional in *E. coli* DH5α.

**Transfer of PhiX174 gene *E* into *H. pylori* by natural transformation or conjugation.** To test whether *H. pylori* was also sensitive to the PhiX174 gene *E*-mediated lysis procedure, we attempted to introduce the plasmid pHPC38 into *H. pylori* strains by natural transformation as well as by bacterial conjugation. Although different *H. pylori* strains were employed as recipients, natural transformation of the plasmid did not result in any transformants with plasmid pHPC38. With the *E. coli* host strain β2155 as a donor and *H. pylori* strain P79 as a recipient, bacterial conjugation resulted in *H. pylori* transconjugants after selection at 35°C. The plasmid was isolated from

P79(pHPC38), and restriction digests revealed a stable replication of the plasmid at the permissive temperature (35°C) on serum plates.

To induce the temperature-dependent expression system, the recombinant strain P79[pHPC38] was grown in Brucella medium at 35°C to an OD<sub>550</sub> of 0.35. The culture was then shifted to 42°C by gentle shaking (90 rpm). After temperature induction, the OD of the culture increased continuously for 3 h, a slight reduction in the OD<sub>550</sub> was visible 4 h after induction, and the minimal OD was measured 9 h after induction (OD<sub>550</sub> = 0.25) (Fig. 2B). Interestingly, the OD of the culture did not increase any further, even after prolonged incubation of up to 48 h (Fig. 2B). In contrast, *H. pylori* P79(pHel2) carrying the empty cloning vector was not hampered in its growth behavior at 42°C for up to 28 h and showed only a slight reduction after 48 h (Fig. 2B).

Analysis of the viability of the induced cultures by plating on serum plates revealed colony formation and growth of the P79(pHel2) control strain at the elevated temperature after 48 h, but no growth of P79(pHPC38) was observed (data not shown), indicating that no lysis-resistant *H. pylori* mutants arose and that the *H. pylori* culture was quantitatively inactivated. The generation of nonculturable coccoid forms of P79(pHPC38) following temperature induction could be excluded by phase-contrast microscopic inspection of the culture. In the P79(pHel2) control, coccoid forms were identified that probably resulted in the reduction of the OD<sub>550</sub> of the culture and a slight reduction in the CFU after 48 h at 42°C. The fluorescence in situ hybridization (FISH) technique, developed recently in our laboratory, detects both vegetative and coccoid forms of *H. pylori* very efficiently (48), but interestingly, FISH did not detect protein *E*-inactivated *H. pylori* P79, indicating that rRNA was not accessible by FISH or was absent in the inactivated bacteria (data not shown).

**Characterization of the inactivated *H. pylori* ghosts by TEM.**






FIG. 3. Characterization of  $\Phi$ IX174 protein E-inactivated *H. pylori* by TEM. P79 (A, C, and E) and P79(pHPC38) (B, D, and F) were grown for 48 h at 42°C in Brucella/FCS. After washing and fixation of bacteria, ultrathin sections were prepared (A to D), and negative staining (E and F) was performed. Ghosts (B, D, and F) show loss of cytoplasmic material and structural integrity. OM, outer membrane. Bars, 1  $\mu$ m (A and B), 0.25  $\mu$ m (C and D), and 0.5  $\mu$ m (E and F).

Next, TEM was used to compare P79 and P79(pHPC38), both grown at 42°C for 48 h (Fig. 3). By viewing ultrathin sections (Fig. 3A and C) or negative-stained specimens (Fig. 3E), *H. pylori* P79 showed no deviation from its vegetative form, and membranes appeared to be intact, indicating that the temperature stress did not have a deleterious effect on the *H. pylori* strain. The situation was completely different for P79(pHPC38). Analysis of ultrathin sections revealed a partial disintegration of the vegetative form, probably due to the

strong disruption of the cytoplasmic membrane and the cell wall (Fig. 3B and D). The outer membrane looked mostly intact, but was sometimes found to be detached from the bacterial cytoskeleton (Fig. 3F, negative stain). The cytoplasmic content apparently did not leak out completely.

To obtain further data on the protein level of P79(pHPC38), the genetically inactivated *H. pylori* cells were analyzed by Western blotting with specific antisera directed against proteins of the outer membrane and the cytoplasm (Table 1).

TABLE 1. Detection of protein antigens in *H. pylori* ghosts

Antigen	Size (kDa)	Antiserum	Reference
AlpA	53	214	37
CagA	129.7	257	36
FlaA	53.3	183	18
Pfr	19.3	198	2
RecA	37.6	263	39
UreB	62	201	17

Proteins such as RecA (39), UreA and UreB (25), and Pfr (2) could be identified in the lysates of the inactivated bacteria with the corresponding specific antisera. A significant reduction of these cytoplasmic proteins compared to the level of typical outer membrane proteins such as AlpA (37) or BabA (21) was not observed, although the Western blot procedure did not provide quantitative data.

Taken together, our data indicated that *H. pylori* P79 was efficiently inactivated by the PhiX-mediated lysis gene expression, but the cytoplasmic content of the bacteria was not completely expelled, as described for other ghosts induced by the PhiX-mediated expression system (46).

**Evaluation of ghosts for prophylactic vaccination in the *H. pylori* mouse model.** Groups of 10 BALB/c mice were orally immunized with three doses of  $2.5 \times 10^9$  ghosts or ghosts plus CT ( $10 \mu\text{g}$  per mouse) as mucosal adjuvant on days 0, 7, and 14. Control mice received PBS (infected group) or no treatment at all (naïve group). Three weeks after the last immunization, all groups of mice except the naïve group were challenged with a streptomycin-resistant, mouse-adapted *H. pylori* strain, P76 ( $10^9$  CFU, three times with 2-day intervals), and 4 weeks later, the animals were sacrificed and gastric colonization was assessed by quantitative culture of P76 on serum plates containing streptomycin.

As compared to the naïve group (Fig. 4A), the infection

control (PBS group, Fig. 4A) shows significant infection, with a median of  $1.85 \times 10^6$  CFU of P76 per g of stomach tissue. The ghost group (Fig. 4A) with a median of  $6.75 \times 10^3$  is significantly reduced, compared to that in the infection control ( $\sim 96\%$ ). Only a slightly stronger reduction in colonization was found with the ghosts used together with CT as adjuvant (Fig. 4A), which resulted in a value of  $3.78 \times 10^3$  as the median of infection ( $\sim 98\%$ ). The reduction in CFU over 2 logs indicates a protection of all animals in the ghost group, as well as the ghost plus CT group.

In an attempt to reproduce and validate the data from the first experiment, a second experiment with a novel batch of bacterial ghosts was performed with the same vaccination strategy. Again, the animals vaccinated with ghosts plus CT showed the highest reduction rate in bacterial load (Fig. 4B), followed by the ghost group (Fig. 4B). The total reduction rate in the ghost group was less efficient than that in the first experiment, but was still significant. Five of 10 mice had enough of a reduction in the amount of CFU per gram of stomach to classify them as protected, with 1 animal showing a sterile immunity.

## DISCUSSION

A major problem for development of an efficient vaccine against *H. pylori* in humans seems to be the choice of an appropriate mucosal adjuvant (44). Due to intestinal toxicity, the dose of heat-labile toxin had to be reduced from 10 to  $5 \mu\text{g}$  in a phase I-II clinical trial, where recombinant *H. pylori* urease was given orally to *H. pylori*-infected human volunteers (33).

In the *H. pylori* mouse model, the use of recombinant vaccine carrier strains, such as attenuated *Salmonella* strains producing the UreA and UreB proteins, revealed protection in a prophylactic immunization experiment without the use of a mucosal adjuvant (6, 17). Although this approach has several




FIG. 4. Prophylactic immunization with *H. pylori* ghosts in two independent experiments. (A) Ghost vaccination I. (B) Ghost vaccination II. Mice were immunized three times at weekly intervals and infected 3 weeks later. Bacterial colonization was assessed by quantitative reisolation of the challenge strain from the stomach by streptomycin selection on serum plates. Values were measured in CFU per gram of stomach tissue. naïve, not infected; PBS, sham-immunized infection control; G, ghosts. Bars indicate the median of each of the groups. In ghost vaccination I, no bacteria were isolated from naïve ( $n = 5$ ) animals. For the PBS group ( $n = 5$ ), the median is  $1.85 \times 10^6$  CFU/g. For ghosts ( $n = 10$ ), the median is  $6.75 \times 10^3$  CFU/g. For ghosts plus CT ( $n = 8$  [two animals died]), the median is  $3.78 \times 10^3$  CFU/g. In two mice, no *H. pylori* cells could be detected. The results for ghost vaccination II are as follows. For the PBS group ( $n = 9$ ), the median is  $1.44 \times 10^6$  CFU/g. For ghosts ( $n = 10$ ), the median is  $1.6 \times 10^5$  CFU/g. In one mouse, no *H. pylori* could be detected. For ghosts plus CT (10 mice), the median is  $5.13 \times 10^3$  CFU/g. Two mice had an infection level of  $<10^3$  CFU/g, and in one mouse, no *H. pylori* could be detected. \*,  $P < 0.05$ .

advantages, one limitation might be that only a restricted number of antigens of the vaccine strain can be produced in the carrier strain. In recent safety and immunogenicity studies of *phoP/phoQ*-deleted *Salmonella enterica* serovar Typhi (11) or strain Ty21a (4) expressing *H. pylori* urease in adult volunteers, the vaccination was found to be safe. Although volunteers mounted an immune response against the *Salmonella* carrier antigens, no volunteer had detectable mucosal immune responses to the urease antigen (4, 11), but three of nine volunteers showed a weak but significant T-cell response to *H. pylori* urease (4).

Our study was aimed to test a further concept of antigen delivery for oral vaccination, the bacterial ghosts, which present a large number of bacterial antigens to the immune system. We hypothesized that this approach might avoid the use of adjuvant due to the rather acid- and protease-resistant nature of the bacterial ghost antigens and the presence of cell wall components with adjuvant properties. These characteristics are not found in soluble purified antigens or bacterial lysates. Thus, bacterial ghosts present a complex combination of structurally intact, rather than single, defined bacterial antigens—such as in the recombinant attenuated *Salmonella* approach—to the immune system.

By definition, bacterial ghosts are empty cell envelopes of gram-negative bacteria, which might be generated by expression of the bacteriophage  $\Phi$ X gene *E* in the bacteria of choice (51). Genetic inactivation of the microorganisms leaves an intact bacterial surface. Chemical or thermal inactivation procedures may lead to the destruction of immunogenic epitopes, which might cause reduced immunogenicity (13, 34). We adapted the method here to *H. pylori* by expressing the *E* gene from a shuttle plasmid in *H. pylori* under the control of the  $\lambda P_{RuvB}$  temperature-inducible promoter. We find a quantitative inactivation of the *H. pylori* culture, without induction of lysis-resistant bacteria. The lack of lysis-resistant mutants in *H. pylori* might be due to the fact that *H. pylori* is not a natural host of the phage  $\Phi$ X, but the mechanism of this genetic inactivation in *H. pylori* is not understood.

Although the negative-staining electron microscopy data indicate that the cytoplasmic membrane is disrupted (Fig. 3), the disruption seems not to be efficient enough that the cytoplasmic content leaks out completely. This could be a problem with the strength of gene *E* expression in *H. pylori*, which might be reduced in comparison to that in *E. coli* or other bacteria. Since we do not have an antiserum against the  $\Phi$ X protein we were unable to test the expression or the putative localization of the protein in *H. pylori* directly. To our knowledge the  $\lambda P_{RuvB}$  promoter has not been used in *H. pylori* before, and nothing is known about its strength. The generation of completely empty *H. pylori* ghosts is still a further aim in our laboratory. This might be attained by stronger expression of the gene *E* or by coexpression of a DNase in *H. pylori*, which would degrade the viscous bacterial DNA to allow a complete emptying of the ghosts.

We used here for the first time *H. pylori* ghosts for vaccination experiments in the *H. pylori* mouse model. Although several gram-negative bacteria have been used successfully to generate bacterial ghosts, only a limited number of vaccination experiments have been performed with this type of antigen presentation. When pigs were vaccinated intramuscularly with

a dose of  $5 \times 10^9$  CFU of *A. pleuropneumoniae* ghosts or formalin-inactivated bacteria, colonization of the respiratory tract after challenge with *A. pleuropneumoniae* was only prevented in the ghost-vaccinated group (19).

In our experiments, we observed a clear reduction of the bacterial load in both independent vaccination experiments compared to the load in the PRS-vaccinated control (Fig. 4). A reduction of approximately 1.5 to 2 logs is considered protective vaccination, since sterile immunity is usually not obtained in the *H. pylori* mouse vaccination models (45). It has been shown in several studies in *Helicobacter* mouse models that without coadministration of a mucosal adjuvant, such as CT, LT, or mutant LT K63, to purified *H. pylori* proteins or whole-cell sonicates, no protective response was observed (7, 27, 29, 30). In our first experiment with *H. pylori* ghosts for vaccination, we obtained a reduction in the *H. pylori* bacterial load that is in the same range or even better than that reported for vaccination experiments with recombinant *Salmonella* producing *H. pylori* urease (1) or *H. pylori* sonicate plus CT (45). If we coadminister *H. pylori* ghosts with CT, the colonization rate can be further reduced, culminating in a sterile immunity in 3 out of 18 animals (Fig. 4).

The second vaccination experiment resulted in clearly less efficient protection in the ghost group. Since the procedure was the same as for the first experiment and the positive and negative controls (sham infected and ghosts plus CT) were comparable to those in the first experiment, it might be that the quality of the ghosts was not as high as that for the first experiment. This would indicate that the expression system has to be optimized for *H. pylori*, and the lysis procedure has to be controlled more rigorously to ensure that a consistent form of ghosts is produced.

In our experiments, we employed only a fixed time window for challenge and reisolation of the bacteria, and a high dose of antigen was used. As demonstrated recently by Sutton et al. (45), the dose of antigen and the time points of vaccination are important parameters that have a consequence on the vaccination result. Thus, our initial data indicate that *H. pylori* ghosts have to be considered as an interesting alternative to the vaccination techniques used so far to control the *H. pylori* infection. In future experiments, it will be necessary to optimize the vaccination parameters carefully for *H. pylori* ghosts. By optimizing gene expression of the *E* gene in *H. pylori* and by improving the treatment conditions after lysis, it might be feasible to generate completely empty ghosts of *H. pylori*. Furthermore, it will be necessary to examine the possible induction of postimmunization gastritis in vaccinated animals, as well as look for key parameters of humoral and cellular immune response elicited by the ghost vaccine.

#### ACKNOWLEDGMENTS

We thank B. P. Burns for critical reading of the manuscript. We are grateful for the receipt of the mouse-adapted *H. pylori* strain by H. Kleanthous, OraVax, Inc.

This work was supported by EVAX Technologies, Munich, Germany, and the Deutsche Forschungsgemeinschaft (grant HA 2697/4-1 to R.H.).

#### REFERENCES

1. Aebischer, T., S. Laforuch, R. Harwitz, F. Brossbacher, and T. F. Meyer. 2001. Immunity against *Helicobacter pylori*: significance of interleukin-4 re-

- ceptor  $\alpha$  chain status and gender of infected mice. *Infect. Immun.* 69:556-558.
2. Bereswill, S., U. Waidner, S. Odenbreit, P. Lichte, F. Faschlinder, G. Bode, and M. Kist. 1998. Structural, functional and mutational analysis of the *ptg* gene encoding a ferritin from *Helicobacter pylori*. *Microbiology* 144:2505-2516.
  3. Bernhardt, T. G., W. D. Roof, and R. Young. 2000. Genetic evidence that the bacteriophage phi X174 hlyA protein inhibits cell wall synthesis. *Proc. Natl. Acad. Sci. USA* 97:4297-4302.
  4. Bumann, D., W. G. Metzger, E. Mansouri, O. Palme, M. Weidland, R. Harwitz, G. Haas, T. Aebischer, B. von Specht, and T. F. Meyer. 2001. Safety and immunogenicity of live recombinant *Salmonella enterica* serovar Typhimurium expressing urease A and B from *Helicobacter pylori* in human volunteers. *Vaccine* 19:445-452.
  5. Corb  s-Thoulez, I., N. Porta, M. Glauser, E. Saraga, A. C. Vasey, R. Haas, J. P. Kraehenb  hl, A. L. Blum, and P. Michetti. 1993. Oral immunization with *Helicobacter pylori* urease B subunit as a treatment against *Helicobacter* infection in mice. *Gastroenterology* 105:115-121.
  6. Corb  s-Thoulez, I. E., S. Hopkins, D. Bachmann, P. F. Seldinger, N. Porta, R. Haas, Y. Zhang-Xia, T. Meyer, H. Boumezziane, A. L. Blum, and J. P. Kraehenb  hl. 1998. Mice are protected from *Helicobacter pylori* infection by nasal immunization with attenuated *Salmonella typhimurium phoP* expressing urease A and B subunits. *Infect. Immun.* 66:581-586.
  7. Cui, S. J., A. Cal, and J. G. Nedrud. 1993. Protection of germ-free mice from infection by *Helicobacter felis* after active oral or passive IgA immunization. *Vaccine* 11:637-642.
  8. Cui, S. J., and J. G. Nedrud. 1991. Oral immunization against *Helicobacter pylori*. *Infect. Immun.* 59:2359-2363.
  9. Delio, C., and M. Meyer. 1997. Maintenance of broad-host-range incompatibility group P and group Q plasmids and transposition of *TnJ* in  *Bartonella henselae* following conjugal plasmid transfer from *Escherichia coli*. *J. Bacteriol.* 179:538-540.
  10. Del Giudice, G., A. Covacci, J. L. Telford, C. Montecucco, and R. Rappuoli. 2001. The design of vaccines against *Helicobacter pylori* and their development. *Annu. Rev. Immunol.* 19:523-563.
  11. DiPetrillo, M. D., T. Tibbitts, H. Kleanthous, K. P. Kilean, and E. L. Holzman. 1999. Safety and immunogenicity of *phoP/phoQ*-deleted *Salmonella typhi* expressing *Helicobacter pylori* urease in adult volunteers. *Vaccine* 17:449-459.
  12. Dolige, C., J. Gust, A. Lee, F. Buck, S. Hartzel, and U. Maass. 1994. Therapeutic immunization against *Helicobacter* infection. *Lancet* 343:914-915.
  13. Ferguson, M., D. J. Wood, and P. D. Minor. 1993. Antigenic structure of poliovirus in inactivated vaccines. *J. Gen. Virol.* 74:685-690.
  14. Ferrero, R. L., J.-M. Thi  ry, M. H  rve, and A. Labigne. 1994. Recombinant antigens prepared from the urease subunits of *Helicobacter* spp.: evidence of protection in a mouse model of gastric infection. *Infect. Immun.* 62:4981-4989.
  15. Fischer, W., D. Schwan, R. Gerland, G. E. Erlefeld, S. Odenbreit, and R. Haas. 1999. A plasmid-based vector system for the cloning and expression of *Helicobacter pylori* genes encoding outer membrane proteins. *Mol. Gen. Genet.* 262:501-507.
  16. Forman, D., D. G. Newell, F. Fullerton, J. W. G. Yarnell, A. R. Stacey, N. Wald, and F. Sitas. 1991. Association between infection with *Helicobacter pylori* and risk of gastric cancer—evidence from a prospective investigation. *Br. Med. J.* 302:1302-1305.
  17. Gomes-Duarte, O. C., B. Lucas, Z. X. Yan, K. Panthel, R. Haas, and T. F. Meyer. 1994. Protection of mice against gastric colonization by *Helicobacter pylori* by single oral dose immunization with attenuated *Salmonella typhimurium* producing urease subunits A and B. *Vaccine* 12:460-471.
  18. Haas, R., T. F. Meyer, and J. P. M. van Putten. 1993. Adagellated mutants of *Helicobacter pylori* generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis. *Mol. Microbiol.* 8:753-760.
  19. Hensel, A., V. H  ter, A. K  ttinger, P. R  tz, C. Stri  tschke, U. Roesler, E. Brand, and W. Labitz. 2000. Intramuscular immunization with genetically inactivated (ghosts) *Acinetobacter pleuropneumoniae* serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. *Vaccine* 18:2945-2953.
  20. Heuvelink, D., and R. Haas. 1998. A stable shuttle vector system for efficient genetic complementation of *Helicobacter pylori* strains by transformation and conjugation. *Mol. Gen. Genet.* 257:519-528.
  21. Iver, D., A. Arngvist, J. Ogren, I. M. Frick, D. Kersalyte, E. T. Inceid, D. E. Berg, A. Covacci, L. Engstrand, and T. Bor  n. 1998. *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. *Science* 279:373-377.
  22. J  cklinger, W., M. P. Sostak, A. Witte, and W. Lubitz. 1999. Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene expression in *Escherichia coli*. *FEMS Microbiol. Lett.* 173:347-352.
  23. Kato, M., Y. Yamaoka, J. J. Kim, R. Reddy, M. Asaka, K. Kashima, M. S. Ochiai, F. A. K. El-Zaatari, D. Y. Graham, and D. H. Kwon. 2000. Regional differences in metronidazole resistance and increasing clarithromycin resistance among *Helicobacter pylori* isolates from Japan. *Antimicrob. Agents Chemother.* 44:2214-2216.
  24. Kotloff, K. L., M. B. Sztein, S. S. Wasserman, G. A. Lososky, S. C. DiLorenzo, and R. L. Walker. 2001. Safety and immunogenicity of oral inactivated whole-cell *Helicobacter pylori* vaccine with adjuvant among volunteers with or without subclinical infection. *Infect. Immun.* 69:3581-3590.
  25. Labigne, A., V. Cussac, and P. Courcoux. 1991. Shuttle cloning and nucleotide sequences of *Helicobacter pylori* genes responsible for urease activity. *J. Bacteriol.* 173:1920-1931.
  26. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. *Nature* 227:680-685.
  27. Lee, A., and M. Chen. 1994. Successful immunization against gastric infection with *Helicobacter* species: use of a cholera toxin B-subunit-whole-cell vaccine. *Infect. Immun.* 62:3594-3597.
  28. Lee, C. K., R. Weitzin, W. D. Thomas, H. Kleanthous, T. H. Ernak, G. Somas, J. E. Hill, S. K. Ackerman, and T. P. Monath. 1995. Oral immunization with recombinant *Helicobacter pylori* urease induces secretory IgA antibodies and protects mice from challenge with *Helicobacter felis*. *J. Infect. Dis.* 172:161-172.
  29. Marchetti, M., B. Arico, D. Burru  l, N. Figura, R. Rappuoli, and P. Ghiara. 1995. Development of a mouse model of *Helicobacter pylori* infection that mimics human disease. *Science* 267:1655-1658.
  30. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizzi, S. Cesinali, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, J. L. Telford, G. Douce, G. Dongan, R. Rappuoli, and P. Ghiara. 1998. Protection against *Helicobacter pylori* infection in mice by intragastric vaccination with *H. pylori* antigens is achieved using a non-toxic mutant of *E. coli* heat-labile enterotoxin (LT) as adjuvant. *Vaccine* 16:33-37.
  31. Michetti, P., I. Corb  s-Thoulez, C. Davin, R. Haas, A. C. Vasey, M. Heliz, J. Bille, J. P. Kraehenb  hl, F. Saraga, and A. L. Blum. 1994. Immunization of BALB/c mice against *Helicobacter felis* infection with *Helicobacter pylori* urease. *Gastroenterology* 107:1002-1011.
  32. Michetti, P., and R. Haas. 1994. Steps towards a vaccine, p. 53-57. In P. M  lterthaler, F. Megraud, P. Michetti, and A. Price (ed.), *The year in Helicobacter pylori* 1994. Current Science, Ltd, London, United Kingdom.
  33. Michetti, P., C. Kreiss, E. L. Kotloff, N. Porta, J. L. Blasco, D. Bachmann, M. Herranz, P. F. Seldinger, I. Corb  s-Thoulez, G. Lososky, R. Nichols, J. Simon, M. Stolte, S. Ackerman, T. P. Monath, and A. L. Blum. 1999. Oral immunization with urease and *Escherichia coli* heat-labile enterotoxin is safe and immunogenic in *Helicobacter pylori*-infected adults. *Gastroenterology* 116:804-812.
  34. Nenci  ni, L., M. Pizzi, M. Bugnoli, T. De Magistris, A. Di Tommaso, F. Giovannoni, R. Manetti, I. Marsili, G. Maltucci, D. Nucci, R. Olivieri, P. Fileri, R. Presentini, L. Villa, J. G. Kresienberg, S. Silvestri, A. Tagliabue, and R. Rappuoli. 1990. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. *Infect. Immun.* 58:1308-1315.
  35. Nomura, A., G. N. Stemmermann, P. H. Chyou, I. Kato, G. I. Perez-Perez, and M. J. Blaser. 1991. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N. Engl. J. Med.* 325:1132-1136.
  36. Odenbreit, S., J. Pils, B. Sedlmayr, E. Gerland, W. Fischer, and R. Haas. 2000. Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science* 287:1497-1500.
  37. Odenbreit, S., M. Till, D. Hofreiter, G. Faller, and R. Haas. 1999. Genetic and functional characterization of the *alpAB* gene locus essential for adhesion of *Helicobacter pylori* to human gastric tissue. *Mol. Microbiol.* 31:1537-1548.
  38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
  39. Schmitt, W., S. Odenbreit, D. Hoenemann, and R. Haas. 1995. Cloning of the *Helicobacter pylori* *recA* gene and functional characterization of its product. *Mol. Gen. Genet.* 248:563-572.
  40. Sch  tz, K., K. Nentzel, B. Dragenits, and A. M. Hirschl. 1995. *Helicobacter pylori* reinfection with identical organisms: transmission by the patients' spouses. *Gut* 36:831-833.
  41. Sipponen, P. 1992. Natural history of gastritis and its relationship to peptic ulcer disease. *Digestion* 51:70-75.
  42. Spurr, A. R. 1969. A low-viscosity epoxy resin embedding medium for electron microscopy. *J. Ultrastruct. Res.* 26:31-43.
  43. Stolte, M., and S. Ekl  . 1993. Healing gastric MALT lymphomas by eradication of *H. pylori*. *Lancet* 342:568.
  44. Sutton, P., and A. Lee. 2000. Review article: *Helicobacter pylori* vaccines—the current status. *Aliment. Pharmacol. Ther.* 14:1107-1118.
  45. Sutton, P., J. Wilson, and A. Lee. 2000. Further development of the *Helicobacter pylori* mouse vaccination model. *Vaccine* 18:2677-2685.
  46. Sostak, M. P., A. Hensel, F. O. Elan, R. Klein, T. Anar, H. Mader, A. Haslberger, S. Bunka, G. Wanner, and W. Lubitz. 1996. Bacterial ghosts: non-living candidate vaccines. *J. Biotechnol.* 44:161-170.
  47. Taylor, D. N., and M. J. Blaser. 1991. The epidemiology of *Helicobacter pylori* infection. *Epidemiol. Rev.* 13:42-59.
  48. Trehanai, K., K. Panthel, S. Strobel, E. Vogt, G. Faller, T. Kirschner, M. Kist, J. Hoesemann, and R. Haas. 2001. Rapid and specific detection of

- Helicobacter pylori* macrolide resistance in gastric tissue by fluorescent in situ hybridisation. *Gut* 46:608-614.
49. Valentine, R. C., R. M. Shapiro, and E. R. Studman. 1968. Regulation of glutamine synthetase. XII. Electron microscopy of the enzyme from *Escherichia coli*. *Biochemistry* 7:2143-2152.
50. Weltzin, R., H. Kleanthous, F. Guirakhoo, T. F. Monath, and C. K. Lee. 1997. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric *Helicobacter felis* infection. *Vaccine* 15: 370-376.
51. Witte, A., G. Wanner, U. Blas, G. Heilmann, M. Szostak, and W. Lubitz. 1990. Endogenous transmembrane channel formation mediated by  $\phi$ X174 lysis protein L. *J. Bacteriol.* 172:4109-4114.

Editor: D. L. Burns